SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ed Don who wrote (61)8/28/1997 9:50:00 PM
From: John McCarthy   of 569
 
Ed -

In terms of giving you the most accurate answer I can, my
answer has to be: I don't know.

Below are some descriptions of Synvisc.

Synvisc(R), a non-pharmacological therapy derived from natural hyaluronan,

Synvisc(R) is composed of modified hyaluronan molecules called hylans, which are uniquely engineered to possess
elasticity and viscosity comparable to healthy young synovial fluid.

This is all a nice way of saying that Synvisc is derived from
chickens - I am assuming you know this.

I am not sure how to differentiate this from Sodium Hyaluronate.

Just by logic, in as much that we are talking about a Medical
Device, I assume that Sodium Hyaluronate approaches or exceeds
the properties that Synvisc was approved on.

You didn't ask - and I don't want to bore you - so tune out
know if you like - but here's my 2 cents at this development.

First - its good news. Competition breeds user awareness.

Second - AHP and Sanofi will go to war along the following
lines:

Sanofi: They will attack on the basis of Price Point.

AHP: They will attempt to bury Sanofi on the basis of stronger
Field Force penetration and more $ in the marketing side.

Sorry, I couldn't be of more help.

Ah - if you did a search on Patents that might turn up something.

Regards,

John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext